Huya Bioscience International expands into South Korea

Chinese pharma company Huya Bioscience International said it has opened its first corporate office in South Korea, in line with its strategy to accelerate drug development by aiding local firms initiate clinical trials and gain approval for new compounds.

Huya was the first company to leverage the Tripartite Cooperation Treaty between Korea, China and Japan to advance product development in Japan based on Chinese data.

The recent signing of an agreement between Huya and the Korean Drug Development Fund (KDDF) will enable Huya and the KDDF to form partnerships with local companies and research institutions to accelerate the development and commercialization of Korean pharmaceutical discoveries for the global markets.